Cello Health (LON:CLL) had its target price lifted by equities researchers at FinnCap from GBX 145 ($1.89) to GBX 160 ($2.09) in a report released on Wednesday, ThisIsMoney.Co.Uk reports. The firm currently has a “corporate” rating on the stock. FinnCap’s price target points to a potential upside of 25.98% from the company’s current price.
Shares of Cello Health stock opened at GBX 127 ($1.66) on Wednesday. Cello Health has a 52-week low of GBX 95 ($1.24) and a 52-week high of GBX 140.07 ($1.83). The stock has a market capitalization of $134.73 million and a price-to-earnings ratio of 20.82. The company has a fifty day moving average of GBX 124.79 and a 200-day moving average of GBX 124.51. The company has a debt-to-equity ratio of 4.70, a quick ratio of 1.23 and a current ratio of 1.28.
In other news, insider Mark Bentley sold 129,800 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of GBX 127 ($1.66), for a total value of £164,846 ($215,400.50).
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.
Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with MarketBeat.com's FREE daily email newsletter.